+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Diabetic Retinopathy Market by Product Type (Anti-VEGF Agents, Corticosteroids, Laser Equipment), Diabetic Type (Non-Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy), Patient Type, End-User - Global Forecast 2025-2030- Product Image
Diabetic Retinopathy Market by Product Type (Anti-VEGF Agents, Corticosteroids, Laser Equipment), Diabetic Type (Non-Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy), Patient Type, End-User - Global Forecast 2025-2030- Product Image
Sale

Diabetic Retinopathy Market by Product Type (Anti-VEGF Agents, Corticosteroids, Laser Equipment), Diabetic Type (Non-Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy), Patient Type, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5788863
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The diabetic retinopathy market is experiencing dynamic change, with new treatment approaches and technologies reshaping patient care and the commercial landscape. Industry stakeholders face a complex mix of operational, regulatory, and patient-centered challenges requiring informed, forward-looking decisions.

Market Snapshot: Diabetic Retinopathy Market Growth and Outlook

The Diabetic Retinopathy Market grew from USD 9.07 billion in 2024 to USD 9.62 billion in 2025. It is expected to continue growing at a CAGR of 6.21%, reaching USD 13.02 billion by 2030. Growth is propelled by an increasing global disease burden, ongoing scientific advancements, and rising adoption of integrated digital health solutions. Competitive pressures and payer expectations further motivate industry innovation and strategic adjustment.

Scope & Segmentation of the Diabetic Retinopathy Market

This report provides comprehensive insight into the core drivers, obstacles, and stakeholder opportunities across the diabetic retinopathy landscape. The analysis delivers segmentation by product, patient, and organizational type, technology adoption, and geography.

  • Product Types: Anti-VEGF agents (aflibercept, bevacizumab, ranibizumab); corticosteroids (dexamethasone, triamcinolone); laser equipment; surgical implants.
  • Diabetic Types: Non-proliferative diabetic retinopathy; proliferative diabetic retinopathy.
  • Patient Types: Adult; pediatric (with distinct treatment considerations).
  • End-User Settings: Ambulatory surgical centers; general clinics; specialty clinics; private hospitals; public hospitals.
  • Geographies: Americas (United States—California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada; Mexico; Brazil; Argentina); Europe, Middle East & Africa (including United Kingdom, Germany, France, and several others); Asia-Pacific (China, India, Japan, Australia, South Korea, among others).
  • Key Technologies: Remote retinal imaging platforms; artificial intelligence-driven diagnostics; biosimilar development; teleophthalmology networks.
  • Leading Companies Covered: AbbVie Inc., AEYE Health, Amgen Inc., ANI Pharmaceuticals, Inc., Bausch + Lomb Corporation, Bayer AG, BCN Peptides, S.A.U., Boehringer Ingelheim International GmbH, Clearside Biomedical, Inc., Eli Lilly and Company, Eyenuk, Inc., EyePoint Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Kodiak Sciences Inc., Novartis AG, Ocugen, Inc., Ocular Therapeutix, Inc., Ocuphire Pharma, Inc., OcuTerra Therapeutics, Opthea Limited, Oxurion NV, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., REGENXBIO Inc., RetinaRisk, RETMARKER, Samsung Biologics Co., Ltd.

Key Takeaways for Senior Decision-Makers

  • Innovative care models are emerging as pharmaceutical and technology players collaborate, driving improved disease monitoring and patient engagement through digital platforms.
  • Biologics and biosimilar therapies redefine therapeutic pathways, promoting personalized treatment and encouraging healthcare providers to move away from uniform protocols.
  • Adaptive clinical trial designs and outcome-based reimbursement models gain favor, enabling faster therapy iteration and better alignment with payer objectives.
  • Geographic differences are significant: North America leads research and adoption, while Asia-Pacific’s rapid investment in healthcare infrastructure and digital tools accelerates uptake.
  • Industry leaders rely on cross-sector partnerships and acquisitions to bridge gaps in product portfolios and extend market reach, strengthening competitive differentiation.
  • Operational pressures intensify as access disparities persist across regions, requiring tailored local strategies to ensure both affordability and high-impact patient care.

Tariff Impact: Navigating Supply Chain and Cost Implications

Revised United States tariff schedules from 2025 have contributed to higher landed costs for ophthalmic equipment and compounded supply constraints for anti-VEGF agents and corticosteroids. Manufacturers have responded with strategic shifts such as localizing manufacturing, diversifying suppliers, and relocating operations closer to demand centers. These actions help mitigate immediate financial impacts while enhancing overall operational resilience in the face of evolving trade policies.

Methodology & Data Sources

This analysis utilizes a robust multi-phase methodology, integrating peer-reviewed literature, regulatory filings, and structured interviews with key stakeholders such as retina specialists and payors. Quantitative surveys and triangulated data from industry and government sources ensure reliable, actionable insights. Scenario modeling is incorporated to evaluate the resilience of core market drivers under varying regulatory and technological conditions.

Why This Report Matters for Diabetic Retinopathy Market Leadership

  • Benefit from a clear, segmented view of the entire diabetic retinopathy ecosystem and its evolving competitive landscape.
  • Identify emerging opportunities and risks resulting from regulatory changes, digital transformation, and globalization of care delivery networks.
  • Support critical investment and strategic planning decisions with actionable research on effective therapeutic innovations and regional differentiation.

Conclusion

This report provides the insight required to guide confident strategic decisions in a complex, fast-moving diabetic retinopathy market. Industry leaders can leverage these findings to drive both immediate results and long-term resilience across global operations.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Adoption of artificial intelligence-enabled diabetic retinopathy screening systems in primary care settings
5.2. Development of long-acting intravitreal drug delivery implants for sustained diabetic retinopathy therapy
5.3. Expansion of teleophthalmology services for remote diabetic retinopathy diagnosis and monitoring
5.4. Emergence of biosimilar anti-VEGF agents to reduce treatment costs in diabetic retinopathy management
5.5. Integration of artificial intelligence with OCT imaging to improve early detection of retinal microaneurysms
5.6. Advancements in gene therapy and CRISPR-based approaches targeting retinal vascular pathology in diabetic retinopathy
5.7. Growing adoption of home-based retinal imaging devices for patient self-monitoring and virtual consultations
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Diabetic Retinopathy Market, by Product Type
8.1. Introduction
8.2. Anti-VEGF Agents
8.2.1. Aflibercept
8.2.2. Bevacizumab
8.2.3. Ranibizumab
8.3. Corticosteroids
8.3.1. Dexamethasone
8.3.2. Triamcinolone
8.4. Laser Equipment
8.5. Surgical Implants
9. Diabetic Retinopathy Market, by Diabetic Type
9.1. Introduction
9.2. Non-Proliferative Diabetic Retinopathy
9.3. Proliferative Diabetic Retinopathy
10. Diabetic Retinopathy Market, by Patient Type
10.1. Introduction
10.2. Adult
10.3. Pediatric
11. Diabetic Retinopathy Market, by End-User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Clinics
11.3.1. General Clinics
11.3.2. Specialty Clinics
11.4. Hospitals
11.4.1. Private Hospitals
11.4.2. Public Hospitals
12. Americas Diabetic Retinopathy Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Diabetic Retinopathy Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Diabetic Retinopathy Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. AbbVie Inc.
15.3.2. AEYE Health
15.3.3. Amgen Inc.
15.3.4. ANI Pharmaceuticals, Inc.
15.3.5. Bausch + Lomb Corporation
15.3.6. Bayer AG
15.3.7. BCN Peptides, S.A.U.
15.3.8. Boehringer Ingelheim International GmbH
15.3.9. Clearside Biomedical, Inc.
15.3.10. Eli Lilly and Company
15.3.11. Eyenuk, Inc.
15.3.12. EyePoint Pharmaceuticals, Inc.
15.3.13. F. Hoffmann-La Roche AG
15.3.14. Kodiak Sciences Inc.
15.3.15. Novartis AG
15.3.16. Ocugen, Inc.
15.3.17. Ocular Therapeutix, Inc.
15.3.18. Ocuphire Pharma, Inc.
15.3.19. OcuTerra Therapeutics
15.3.20. Opthea Limited
15.3.21. Oxurion NV
15.3.22. Pfizer, Inc.
15.3.23. Regeneron Pharmaceuticals, Inc.
15.3.24. REGENXBIO Inc.
15.3.25. RetinaRisk
15.3.26. RETMARKER
15.3.27. Samsung Biologics Co., Ltd.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. DIABETIC RETINOPATHY MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. DIABETIC RETINOPATHY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. DIABETIC RETINOPATHY MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. DIABETIC RETINOPATHY MARKET: RESEARCHAI
FIGURE 24. DIABETIC RETINOPATHY MARKET: RESEARCHSTATISTICS
FIGURE 25. DIABETIC RETINOPATHY MARKET: RESEARCHCONTACTS
FIGURE 26. DIABETIC RETINOPATHY MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. DIABETIC RETINOPATHY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY TRIAMCINOLONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY TRIAMCINOLONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY LASER EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY LASER EQUIPMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY SURGICAL IMPLANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY SURGICAL IMPLANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY NON-PROLIFERATIVE DIABETIC RETINOPATHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY NON-PROLIFERATIVE DIABETIC RETINOPATHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PROLIFERATIVE DIABETIC RETINOPATHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PROLIFERATIVE DIABETIC RETINOPATHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 101. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 102. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 103. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2024 (USD MILLION)
TABLE 104. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2025-2030 (USD MILLION)
TABLE 105. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 106. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 107. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2024 (USD MILLION)
TABLE 108. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2025-2030 (USD MILLION)
TABLE 109. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 110. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 111. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 112. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 113. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 114. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 115. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 116. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 117. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 118. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 119. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2024 (USD MILLION)
TABLE 120. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2025-2030 (USD MILLION)
TABLE 121. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 122. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 123. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2024 (USD MILLION)
TABLE 124. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2025-2030 (USD MILLION)
TABLE 125. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 126. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 127. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 128. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 129. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 130. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 131. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 132. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 199. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 200. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 201. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2024 (USD MILLION)
TABLE 202. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2025-2030 (USD MILLION)
TABLE 203. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 204. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 205. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2024 (USD MILLION)
TABLE 206. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2025-2030 (USD MILLION)
TABLE 207. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 208. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 209. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 210. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 211. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 212. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 213. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 214. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 215. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 216. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 217. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2024 (USD MILLION)
TABLE 218. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2025-2030 (USD MILLION)
TABLE 219. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 220. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 221. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2024 (USD MILLION)
TABLE 222. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2025-2030 (USD MILLION)
TABLE 223. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 224. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 225. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 226. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 227. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 228. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 229. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 230. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 231. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 232. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 247. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 248. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 249. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2024 (USD MILLION)
TABLE 250. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2025-2030 (USD MILLION)
TABLE 251. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 252. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 253. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2024 (USD MILLION)
TABLE 254. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2025-2030 (USD MILLION)
TABLE 255. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 256. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 257. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 258. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 259. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 260. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 261. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 262. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 263. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 264. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 265. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2024 (USD MILLION)
TABLE 266. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2025-2030 (USD MILLION)
TABLE 267. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 268. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 269. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2024 (USD MILLION)
TABLE 270. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2025-2030 (USD MILLION)
TABLE 271. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 272. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 273. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 274. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 275. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 276. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 277. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 278. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 295. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 296. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2024 (USD MILLION)
TABLE 298. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2025-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 300. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2025-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 304. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 306. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 308. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 310. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 311. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 312. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2024 (USD MILLION)
TABLE 314. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2025-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 316. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2024 (USD MILLION)
TABLE 318. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2025-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 320. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 321. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 322. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 323. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 324. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 325. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 326. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 327. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 328. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 329. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2024 (USD MILLION)
TABLE 330. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2025-2030 (USD MILLION)
TABLE 331. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 332. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 333. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2024 (USD MILLION)
TABLE 334. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2025-2030 (USD MILLION)
TABLE 335. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 336. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 337. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 338. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2025-2030

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Diabetic Retinopathy market report include:
  • AbbVie Inc.
  • AEYE Health
  • Amgen Inc.
  • ANI Pharmaceuticals, Inc.
  • Bausch + Lomb Corporation
  • Bayer AG
  • BCN Peptides, S.A.U.
  • Boehringer Ingelheim International GmbH
  • Clearside Biomedical, Inc.
  • Eli Lilly and Company
  • Eyenuk, Inc.
  • EyePoint Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche AG
  • Kodiak Sciences Inc.
  • Novartis AG
  • Ocugen, Inc.
  • Ocular Therapeutix, Inc.
  • Ocuphire Pharma, Inc.
  • OcuTerra Therapeutics
  • Opthea Limited
  • Oxurion NV
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • REGENXBIO Inc.
  • RetinaRisk
  • RETMARKER
  • Samsung Biologics Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages199
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 9.62 Billion
Forecasted Market Value ( USD ) by 2030 $ 13.02 Billion
Compound Annual Growth Rate6.2%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Retinal Disease Therapy Options Market by Indication, Therapy Type, Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2030 - Product Image

Retinal Disease Therapy Options Market by Indication, Therapy Type, Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Retinal Disorder Treatment Market by Disease (Age-Related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion), Drug Class (Anti-VEGF, Corticosteroids), Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2030 - Product Image

Retinal Disorder Treatment Market by Disease (Age-Related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion), Drug Class (Anti-VEGF, Corticosteroids), Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Diabetic Retinopathy Market Size, Share & Trends Analysis Report by Type (Proliferative Diabetic Retinopathy), Management (Anti-VEGF, Intraocular Steroid Injection, Laser Surgery, Vitrectomy), Region and Segment Forecasts, 2025 - 2030 - Product Image

Diabetic Retinopathy Market Size, Share & Trends Analysis Report by Type (Proliferative Diabetic Retinopathy), Management (Anti-VEGF, Intraocular Steroid Injection, Laser Surgery, Vitrectomy), Region and Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Diabetic Retinopathy Treatment - Global Strategic Business Report - Product Image

Diabetic Retinopathy Treatment - Global Strategic Business Report

  • Report
  • 273 Pages
  • Global
From
Diabetic Retinopathy Treatment Market Size Analysis Report - Market Share, Forecast Trends and Outlook (2025-2034) - Product Image

Diabetic Retinopathy Treatment Market Size Analysis Report - Market Share, Forecast Trends and Outlook (2025-2034)

  • Report
  • 400 Pages
  • Global
From

About the Diabetic Retinopathy Market

Diabetic Retinopathy (DR) is a medical condition that affects the eyes of people with diabetes. It is caused by damage to the blood vessels in the retina, the light-sensitive layer of tissue at the back of the eye. DR can lead to vision loss and blindness if left untreated. Optical imaging technologies, such as optical coherence tomography (OCT) and fundus photography, are used to diagnose and monitor DR. These technologies allow for early detection and treatment of DR, which can help to reduce the risk of vision loss. In addition to imaging technologies, there are a number of treatments available for DR, including laser photocoagulation, intravitreal injections, and vitrectomy. These treatments can help to reduce the risk of vision loss and improve vision in those with DR. The DR market is a rapidly growing market, driven by the increasing prevalence of diabetes and the need for early detection and treatment of DR. Companies in the DR market include Carl Zeiss Meditec, Topcon Corporation, Optos, Nidek, and Heidelberg Engineering. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.